Scleroderma

162 registered clinical trials studyying Scleroderma — 35 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases NCT07470151	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	N/A
Recruiting	Transcriptomic Study of Cutaneous Fibroblasts in Scleroderma NCT07256418	Centre Hospitalier Universitaire Dijon	—
Not Yet Recruiting	Evaluating Tools to Communicate Scleroderma Research Results to Patients - Trial #1 NCT06373263	Lady Davis Institute	N/A
Recruiting	Investigating the Effectiveness of the Biopsychosocial Model-Based Exercise Approach in Children and Adults Di NCT07292961	Hacettepe University	N/A
Recruiting	Patients Diagnosed With Scleroderma: Physical Performance and Functionality NCT07183072	Hacettepe University	—
Recruiting	Patients Diagnosed With Scleroderma and Their Chewing and Swallowing Performance NCT07182981	Hacettepe University	—
Recruiting	AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Ritux NCT06991114	Artiva Biotherapeutics, Inc.	Phase 2
Completed	RENEW-AI: Personalizing Scleroderma Management With an AI Health Coach NCT06999226	University of Michigan	N/A
Active Not Recruiting	Brain Boost Program to Improve Cognitive Function in People With Systemic Sclerosis NCT06880627	University of Michigan	N/A
Recruiting	Efficacy and Safety of HN2301 in Autoimmune Diseases（AIDs） NCT06801119	Shenzhen MagicRNA Biotechnology Co., Ltd	Phase 1
Not Yet Recruiting	Ultrasound and Electrophysiology Study of Hand in Systemic Sclerosis Patients and Contributors of Hand Dysfunc NCT06776575	Assiut University	—
Not Yet Recruiting	Delving Into Participation Trends of Scleroderma Clinical Trials NCT06264492	Power Life Sciences Inc.	—
Recruiting	Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE) NCT06843239	Zura Bio Inc	Phase 2
Completed	Evaluating the Effect of Questionnaire Context on the Reporting of Somatic Items Among People With Systemic Sc NCT06772896	Lady Davis Institute	N/A
Enrolling By Invitation	Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic Diseases NCT06763783	Region Skane	Phase 4
Not Yet Recruiting	Ultrasonic COmparison of Salivary Glands in Autoimmune Diseases (COUGAR) NCT06680310	University Hospital, Brest	—
Not Yet Recruiting	6-minute Pegboard Ring Test in Patients With Scleroderma NCT06588959	Yasemin GEDIKLI	—
Recruiting	TENS in Scleroderma NCT06646913	University of Michigan	Phase 1
Recruiting	Respiratory Muscle Strength and Aerobic Capacity in Scleroderma NCT06554132	Firat University	—
Recruiting	Skeletal Muscle Function in Interstitial Lung Disease NCT03800017	University of British Columbia	N/A
Recruiting	RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in NCT06328777	Cabaletta Bio	Phase 1 / Phase 2
Recruiting	Investigation of Respiratory Muscle Sarcopenia in Patients With Systemic Sclerosis NCT06598982	Selcuk University	—
Recruiting	Connective Tissue Massage in Scleroderma NCT06474910	Firat University	N/A
Recruiting	Platform Clinical Study for Conquering Scleroderma NCT06195072	Scleroderma Research Foundation, Inc.	Phase 2
Completed	Hyaluronidase Via LADD Scleroderma-induced Microstomia NCT05995626	University of Nebraska	EARLY_Phase 1
Recruiting	Rheumatology Diet Study NCT06339957	University of Central Florida	—
Active Not Recruiting	Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) NCT05925803	AstraZeneca	Phase 3
Completed	Self-management Telehealth Program for Scleroderma NCT06990386	Khon Kaen University	N/A
Not Yet Recruiting	Calcinosis Reduction by Pyrophosphate in SSC NCT04966416	Szeged University	N/A
Unknown	Co-designing Digital Ulcers Opportunities With Patients and Clinicians NCT05785403	King's College London	—
Unknown	Effectiveness of ESWT and PNF in Scleroderma With Calcinosis NCT05870852	Istanbul University	N/A
Enrolling By Invitation	Elastography Ultrasound in Localized Scleroderma (Morphea) Study NCT06847750	The Hospital for Sick Children	—
Recruiting	A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune NCT06587828	TScan Therapeutics, Inc.	—
Completed	Stress, Scleroderma and Quality of Life NCT05617066	Asociación Española de Esclerodermia	N/A
Recruiting	Preventive Effect of Clopidogrel on the Systemic Sclerosis Development Risk NCT05098704	University Hospital, Bordeaux	Phase 2 / Phase 3
Unknown	Effectiveness of Telerehabilitation on Scleroderma NCT04563481	Istanbul University	N/A
Active Not Recruiting	MRI for Screening and Monitoring Scleroderma ILD NCT05204355	University of Kansas Medical Center	—
Terminated	Effectiveness of the EmoLED Medical Device in the Healing of Digital Ulcers in Patients With Scleroderma. NCT05181644	Emoled	N/A
Recruiting	Clinico-biological Collection to Investigate the Physiopathology of Systemic Autoimmune Diseases NCT05251415	University Hospital, Toulouse	—
Unknown	COvid-19 Vaccine Booster in Immunocompromised Rheumatic Diseases NCT05236491	Paul R Fortin	Phase 2 / Phase 3
Unknown	Rheopheresis for Raynaud's and Digital Ulcers in Systemic Sclerosis NCT05204784	Peter Korsten	N/A
Completed	Validity and Reliability of the Turkish Version of HAnDE NCT06536595	Gazi University	—
Unknown	Effectiveness of Bosentan Therapy in Patients With Systemic scleRosis and Progressive Digital ulcEr Disease. NCT05168215	Elpen Pharmaceutical Co. Inc.	—
Completed	Rituxmab Versus IL-6 in Treating ILD NCT05963048	Assiut University	Phase 2 / Phase 3
Recruiting	Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Init NCT05635266	Sanguine Biosciences	—
Unknown	Rehabilitation Program in Patients With Scleroderma NCT05041868	Centro Universitário Augusto Motta	N/A
Unknown	A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma NCT05085444	Zhejiang University	EARLY_Phase 1
Recruiting	Sildenafil for Early Pulmonary Vascular Disease in Scleroderma NCT04797286	Johns Hopkins University	Phase 2
Completed	SPIN Self-Management Feasibility Trial With Progression to Full-scale Trial (SPIN-SELF) NCT04246528	Lady Davis Institute	N/A
Completed	Upper Extremity Home Exercises in Patients With Scleroderma NCT05080738	Pamukkale University	N/A
Completed	RENEW Scleroderma: A Peer-Mentored, Web Intervention for Resilience-based, Energy Management to Enhance Wellbe NCT04908943	University of Michigan	N/A
Terminated	Laser Treatment for the Improvement of Scars and Scleroderma NCT04567537	Massachusetts General Hospital	N/A
Terminated	A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients NCT04837131	Michael M. Pham	Phase 2
Completed	Prevalence of Hyperprolactinemia in Systemic Scleroderma NCT04746313	University Hospital, Lille	—
Completed	Telerehabilitation on Hand-Affected Scleroderma NCT04684225	Istanbul University	N/A
Unknown	Lung Clearance Index to Identify Scleroderma Patients at Risk for ILD NCT04535245	National Jewish Health	—
Enrolling By Invitation	UVA-1 for Treatment of Skin Tightening and Improvement of Hand Function in Scleroderma NCT04875078	University of Utah	N/A
Completed	Feasibility and Preliminary Effects of the Resilience-based, Energy Management to Enhance Wellbeing in Systemi NCT04588714	University of Michigan	N/A
Completed	Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis NCT04464434	UMC Utrecht	Phase 4
Recruiting	Rheumatology Patient Registry and Biorepository NCT04402086	Yale University	—
Completed	The Effect of a Self-Management Program on Individuals With Scleroderma NCT06095921	Emirhan Karakuş	N/A
Recruiting	Cohort of Patients With Systemic Sclerosis Within the Framework of the RESO Reference Centre NCT04265144	University Hospital, Bordeaux	N/A
Completed	The Effects of Botulinum Toxin on Oral Aperture in Patients With Scleroderma NCT04523506	University of Texas Southwestern Medical Center	EARLY_Phase 1
Unknown	Evaluating Gut Imaging and Stool Biomarkers in Patients With Scleroderma-associated Gastrointestinal Disease NCT04630782	Singapore General Hospital	—
Completed	Evaluation of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Togethe NCT04335279	Lady Davis Institute	N/A
Completed	Yoga Adjunct for Scleroderma NCT04491396	Medical University of South Carolina	N/A
Withdrawn	Hyaluronidase in Treating Oral Microstomia in Patients With Sclerosing Skin Disease NCT04656704	Brigham and Women's Hospital	EARLY_Phase 1
Terminated	Assessment of the Prevalence of Olfactory Disorders in Systemic Scleroderma NCT04178616	University Hospital, Lille	N/A
Terminated	A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea) NCT03740724	Castle Creek Biosciences, LLC.	Phase 1 / Phase 2
Completed	Mouth Handicap in Systemic Sclerosis NCT04273386	Istanbul University	N/A
Completed	The Effect of Physiotherapy Program in Scleroderma Patients NCT04179292	Istanbul University	N/A
Completed	SPIN Self-Management Feasibility Trial NCT03914781	Lady Davis Institute	N/A
Terminated	Smartphone Mindfulness Meditation for Patients With Rheumatic Diseases NCT03937856	Johns Hopkins University	N/A
Completed	Cardiac Assessment by PV Loop in IPAH and Scleroderma PAH NCT04610788	Johns Hopkins University	—
Completed	Local Injection of Ozone Versus Methylprednisolone Acetate in Carpal Tunnel Syndrome of Scleroderma Patients NCT03742466	Assiut University	N/A
Withdrawn	CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated ILD and PH NCT03726398	Franz Rischard, DO	Phase 2 / Phase 3
Unknown	Endothelial Biomarkers of Systemic Sclerosis-associated Pulmonary Hypertension NCT03459716	Louisiana State University Health Sciences Center in New Orleans	—
Terminated	Cardiac Safe Transplants for Systemic Sclerosis NCT03593902	Northwestern University	Phase 2 / Phase 3
Completed	The Scleroderma Patient-centered Intervention Network (SPIN) Support Group Leader Education Program Feasibilit NCT03508661	Lady Davis Institute	N/A
Completed	Scleroderma Patient-centered Intervention Network (SPIN) Hand Program NCT03419208	Lady Davis Institute	N/A
Terminated	Mindfulness Based Stress Reduction in Rheumatic Diseases NCT03411057	Johns Hopkins University	—
Withdrawn	Functional Luminal Imaging Probe (FLIP) Topography Use in Patients With Scleroderma and Trouble Swallowing NCT03270722	Stanford University	N/A
Recruiting	Maternal Autoimmune Disease Research Alliance (MADRA) Registry NCT03276923	Duke University	—
Completed	Optical Elastography of Systemic Sclerosis Skin NCT02835196	The University of Texas Health Science Center, Houston	—
Completed	Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc) NCT03274076	University of Michigan	Phase 1 / Phase 2
Completed	Brentuximab Vedotin for Systemic Sclerosis NCT03222492	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1 / Phase 2
Completed	MRI Quantification of Pulmonary Fibrosis in Scleroderma Patients NCT03207997	Assistance Publique - Hôpitaux de Paris	N/A
Completed	Scleroderma Patient-centered Intervention Network (SPIN) Hand Program Feasibility Study NCT03092024	Lady Davis Institute	N/A
Completed	Transcutaneous Electroacupuncture for Gastric Complications of Scleroderma NCT03294616	Johns Hopkins University	N/A
Unknown	Effects of Whole Body Vibration Training in Patients With Interstitial Lung Disease NCT03560154	Istanbul University	N/A
Completed	Study to Compare the Efficacy of Mycophenolate Mofetil in Systemic Sclerosis Related Early Interstitial Lung D NCT02896205	Post Graduate Institute of Medical Education and Research, Chandigarh	Phase 3
Completed	Bosentan Treatment of Digital Ulcers Related to Systemic Sclerosis NCT02798055	Elpen Pharmaceutical Co. Inc.	—
Completed	Riociguat in Scleroderma Associated Digital Ulcers NCT02915835	Dinesh Khanna, MD, MS	Phase 2
Completed	Effectiveness of a Home-based, Self-administered Exercise Program for Hands in Patients With Systemic Sclerosi NCT04481984	Cukurova University	N/A
Completed	Novel Rehabilitation Strategies to Improve Arm Function in Patients With Scleroderma NCT02837549	University of Michigan	N/A
Completed	Ozone Therapy in the Treatment of Digital Ulcers in Patients With Systemic Sclerosis NCT02733978	Assiut University	N/A
Terminated	Duke Scleroderma Clinic Patient Registry NCT02851875	Duke University	—
Completed	Taking Charge of Systemic Sclerosis NCT02494401	University of Michigan	N/A
Completed	Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis NCT02370693	Northwestern University	Phase 2
Withdrawn	Comparative Effectiveness Trial in the Treatment of Pediatric Plaque Morphea NCT02680717	Medical College of Wisconsin	Phase 1
Withdrawn	A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diff NCT02588625	Bristol-Myers Squibb	Phase 2
Completed	Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma NCT02426229	Medical University of South Carolina	Phase 1
Completed	The Effect of Ethanol Extract Physalis Angulata Linn. in Scleroderma Patients With Standard Therapy NCT03141125	Indonesia University	N/A
Withdrawn	Pregnancy and Medically Assisted Conception in Rare Diseases NCT02450396	Assistance Publique - Hôpitaux de Paris	—
Completed	Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR) NCT02396238	Cytori Therapeutics	N/A
Withdrawn	Scleroderma Treatment With Celution Processed ADRCs Registry NCT02328625	Cytori Therapeutics	—
Unknown	PatientSpot Formerly Known as ArthritisPower NCT03840928	Global Healthy Living Foundation	—
Completed	Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse Scleroderma NCT02370784	Robyn T. Domsic, MD, MPH	Phase 2
Completed	Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome NCT02165111	Johns Hopkins University	Phase 3
Completed	Hands on - a Hand Care Guide in Systemic Sclerosis NCT02610842	University of Campinas, Brazil	N/A
Completed	Endothelial Microparticles in Systemic Sclerosis Pulmonary Hypertension NCT02331225	Louisiana State University Health Sciences Center in New Orleans	—
Unknown	Effects of Probiotics on Gastrointestinal Symptoms and on the Immune System in Patients With Systemic Sclerosi NCT02302352	Federal University of São Paulo	Phase 3
Completed	Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD NCT01862926	Royal Brompton & Harefield NHS Foundation Trust	Phase 2 / Phase 3
Completed	Zibotentan Better Renal Scleroderma Outcome Study NCT02047708	University College, London	Phase 2
Completed	The Scleroderma Biorepository and Pathogenesis Study (STOP Scleroderma) NCT02887495	George Washington University	—
Withdrawn	Divalproex Sodium in the Treatment of the Cutaneous Manifestations of Scleroderma NCT02166229	Yale University	Phase 1 / Phase 2
Completed	Scleroderma ARFI Imaging of the Skin NCT02006420	University of Michigan	—
Completed	Novel Screening Strategies for Scleroderma PAH NCT01959815	University of Michigan	—
Completed	At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurolo NCT01931644	Sanguine Biosciences	—
Completed	Gastroesophageal Reflux Treatment in Scleroderma NCT01878526	Khon Kaen University	Phase 3
Completed	Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease NCT01570764	Assistance Publique - Hôpitaux de Paris	Phase 3
Completed	Calcinosis in a Single-Center Scleroderma Population NCT02062125	Rutgers, The State University of New Jersey	—
Completed	Autologous Stem Cell Transplantation for Progressive Systemic Sclerosis NCT01895244	University Hospital Tuebingen	Phase 2
Unknown	Regulatory B Cells in Inflammatory Rheumatisms and Biomarkers of Response to Biologic Treatments NCT01642706	University Hospital, Montpellier	—
Completed	Morbidity and Mortality Follow Up for the Scleroderma Lung Study NCT01762449	Duke University	—
Unknown	Empirical Comparative Study of Variation Blood Level Antibody Vitamin D at Scleroderma (SSc) Patients Compared NCT01553890	Meir Medical Center	N/A
Withdrawn	Probiotics in Patients With Moderate-to-severe Distention/ Bloating From Systemic Sclerosis NCT01497743	University of Michigan	Phase 4
Completed	IL1-TRAP, Rilonacept, in Systemic Sclerosis NCT01538719	Boston University	Phase 1 / Phase 2
Completed	Vaccination in Inflammatory Rheumatic Disease (VACCIMIL). The Impact of Antirheumatic Treatment on Antibody Re NCT02240888	Region Skane	N/A
Withdrawn	Campath-1h Phase I/II Pilot Trial as Immunoablative Therapy for Refractory Systemic Sclerosis NCT01639573	Children's Hospital Los Angeles	—
Recruiting	Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford NCT01793168	Sanford Health	—
Completed	Finger Hardness Measure in Scleroderma NCT01111786	Mayo Clinic	—
Completed	A Study of the Safety and Tolerability of MEDI-551 in Scleroderma NCT00946699	MedImmune LLC	Phase 1
Completed	Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis NCT01093885	University of Pennsylvania	N/A
Completed	A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma NCT01117298	Sanjay Gandhi Postgraduate Institute of Medical Sciences	Phase 3
Completed	Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II) NCT00883129	Michael Roth	Phase 2
Completed	A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With Scleroderma NCT00930683	MedImmune LLC	Phase 1
Completed	Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine NCT00775463	United Therapeutics	Phase 2
Completed	Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary Fibrosis NCT00764309	Bristol-Myers Squibb	Phase 1 / Phase 2
Terminated	Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma NCT01545427	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	Phase 2
Completed	Duke Autoimmunity in Pregnancy Registry NCT00513591	Duke University	—
Completed	A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon NCT00498615	Johns Hopkins University	Phase 3
Completed	Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon NCT00419419	MediQuest Therapeutics	Phase 3
Completed	Premature Coronary Atherosclerosis in Scleroderma NCT00372398	Tuen Mun Hospital	—
Recruiting	Scleroderma Registry & Repository at the Hospital for Special Surgery NCT01656447	Hospital for Special Surgery, New York	—
Completed	Sleep Disturbances and Pulmonary Artery/Aorta Diameter in Scleroderma Patient NCT00566137	Northwell Health	—
Terminated	Allogeneic Hematopoietic Stem Cell Transplantation (NST) for Patients With Systemic Sclerosis NCT00282425	Richard Burt, MD	Phase 1
Completed	Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients NCT00377949	Georgetown University	—
Completed	Genesis of Scleroderma: Role of Environmental Factors in 100 Patients With Scleroderma and 300 Controls NCT00213525	University Hospital, Rouen	—
Completed	Open-label Study With Bosentan in Interstitial Lung Disease NCT00319033	Actelion	Phase 2 / Phase 3
Completed	Effectiveness and Safety of Lidocaine for Scleroderma NCT00740285	Federal University of São Paulo	Phase 2 / Phase 3
Terminated	Comparison of Esophageal and Anorectal Manometry Catheters NCT00204763	University of Utah	Phase 4
Terminated	Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma Patients NCT00040651	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Phase 1
Completed	UVA1 Light for Treatment of Scleroderma and Similar Conditions NCT00476801	University of Michigan	N/A
Completed	Psychological Treatments for Scleroderma NCT00007267	Johns Hopkins University	Phase 2
Completed	High Dose Cyclophosphamide for Treatment of Scleroderma NCT00501995	Johns Hopkins University	Phase 3
Completed	Scleroderma Registry NCT00074568	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	—
Completed	Oral Type I Collagen for Relieving Scleroderma NCT00005675	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Phase 2
Completed	Optical Biopsy of Human Skin in Conjunction With Laser Treatment NCT00540566	University of California, Irvine	—
Terminated	UVA1 Light for Scleroderma and Similar Conditions NCT00476697	University of Michigan	N/A
Completed	Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients W NCT00043706	Genzyme, a Sanofi Company	Phase 1 / Phase 2
No Longer Available	Post Marketing Surveillance Study of Cuprimine NCT01374282	Merck Sharp & Dohme LLC	—